Codexis, Inc. – NASDAQ:CDXS
Codexis stock price today
$3.029
-1.96
-39.3%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Codexis stock price monthly change
+55.94%
month
Codexis stock price quarterly change
+55.94%
quarter
Codexis stock price yearly change
+48.07%
year
Codexis key metrics
Market Cap | 400.78M |
Enterprise value | 197.13M |
P/E | -7.7 |
EV/Sales | 1.42 |
EV/EBITDA | -9.11 |
Price/Sales | 1.92 |
Price/Book | 1.84 |
PEG ratio | 0.14 |
EPS | -0.93 |
Revenue | 74.23M |
EBITDA | -23.15M |
Income | -65.12M |
Revenue Q/Q | 31.51% |
Revenue Y/Y | -36.13% |
Profit margin | -24.24% |
Oper. margin | -22.88% |
Gross margin | 72.56% |
EBIT margin | -22.88% |
EBITDA margin | -31.19% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCodexis stock price history
Codexis stock forecast
Codexis financial statements
| Jun 2023 | 21.32M | -11.52M | -54.04% |
|---|---|---|---|
| Sep 2023 | 9.27M | -34.90M | -376.29% |
| Dec 2023 | 26.56M | -7.19M | -27.08% |
| Mar 2024 | 17.07M | -11.50M | -67.39% |
| Mar 2024 | 17.07M | -11.50M | -67.39% |
|---|---|---|---|
| Sep 2025 | 15.72M | -11.12M | -70.73% |
| Oct 2025 | 16.36M | -12.57M | -76.84% |
| Dec 2025 | 19.43M | -10.89M | -56.08% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 206761000 | 82.63M | 39.96% |
|---|---|---|---|
| Sep 2023 | 154455000 | 62.94M | 40.76% |
| Dec 2023 | 136561000 | 49.94M | 36.57% |
| Mar 2024 | 149559000 | 70.29M | 47% |
| Jun 2023 | -16.08M | -1.57M | 6.92M |
|---|---|---|---|
| Sep 2023 | -16.30M | -1.10M | -108K |
| Dec 2023 | -11.03M | 1.10M | 0 |
| Mar 2024 | -7.78M | -28.56M | 29.28M |
Codexis alternative data
| Aug 2023 | 248 |
|---|---|
| Sep 2023 | 248 |
| Oct 2023 | 248 |
| Nov 2023 | 248 |
| Dec 2023 | 248 |
| Jan 2024 | 248 |
| Feb 2024 | 248 |
| Mar 2024 | 174 |
| Apr 2024 | 174 |
| May 2024 | 174 |
| Jun 2024 | 174 |
| Jul 2024 | 174 |
Codexis other data
51.14%
-39.92%
of CDXS is owned by hedge funds
90
-71
33.41M
-26.16M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 75499 |
| Jan 2023 | 0 | 75499 |
| Feb 2023 | 0 | 75499 |
| Mar 2023 | 0 | 159043 |
| Apr 2023 | 0 | 71428 |
| Sep 2023 | 90963 | 0 |
| Nov 2023 | 0 | 20000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DORGAN BYRON L director | Common Stock | 20,000 | $2.11 | $42,160 | ||
Purchase | NORRETT KEVIN officer: Chief Operating Officer | Common Stock | 9,000 | $1.72 | $15,480 | ||
Purchase | RYALI SRIRAM officer: Chief Financial Officer | Common Stock | 11,650 | $1.7 | $19,852 | ||
Purchase | FITZGERALD MARGARET NELL officer: See Remarks | Common Stock | 11,834 | $1.7 | $20,070 | ||
Purchase | DILLY STEPHEN GEORGE director, officer: See Remarks | Common Stock | 58,479 | $1.73 | $100,935 | ||
Option | NICOLS JOHN J director | Common Stock | 35,714 | $1.97 | $70,357 | ||
Sale | NICOLS JOHN J director | Common Stock | 35,714 | $4.14 | $147,892 | ||
Option | NICOLS JOHN J director | Stock Option (Right to Buy) | 35,714 | $1.97 | $70,357 | ||
Sale | NICOLS JOHN J director | Common Stock | 35,714 | $4.24 | $151,392 | ||
Option | NICOLS JOHN J director | Stock Option (Right to Buy) | 35,714 | $1.97 | $70,357 |
| Patent |
|---|
Application Filling date: 12 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 6 May 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 26 Oct 2020 Issue date: 30 Aug 2022 |
Grant Utility: Human alpha-galactosidase variants Filling date: 19 Dec 2019 Issue date: 30 Aug 2022 |
Application Filling date: 28 Apr 2022 Issue date: 25 Aug 2022 |
Grant Utility: Engineered tyrosine ammonia lyase Filling date: 14 Jan 2021 Issue date: 23 Aug 2022 |
Application Filling date: 30 Jun 2020 Issue date: 11 Aug 2022 |
Grant Filling date: 26 Mar 2020 Issue date: 2 Aug 2022 |
Application Filling date: 12 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 28 Mar 2022 Issue date: 14 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q4 2022 23 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. John J. Nicols (1964) Pres, Chief Executive Officer & Director | $1,170,000 |
Mr. Ross Taylor Jr., M.B.A. (1963) Senior Vice President & Chief Financial Officer | $604,960 |
-
What's the price of Codexis stock today?
One share of Codexis stock can currently be purchased for approximately $3.03.
-
When is Codexis's next earnings date?
Unfortunately, Codexis's (CDXS) next earnings date is currently unknown.
-
Does Codexis pay dividends?
No, Codexis does not pay dividends.
-
How much money does Codexis make?
Codexis has a market capitalization of 400.78M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 49.39% to 70.14M US dollars.
-
What is Codexis's stock symbol?
Codexis, Inc. is traded on the NASDAQ under the ticker symbol "CDXS".
-
What is Codexis's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Codexis?
Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Codexis's key executives?
Codexis's management team includes the following people:
- Mr. John J. Nicols Pres, Chief Executive Officer & Director(age: 61, pay: $1,170,000)
- Mr. Ross Taylor Jr., M.B.A. Senior Vice President & Chief Financial Officer(age: 62, pay: $604,960)
-
How many employees does Codexis have?
As Jul 2024, Codexis employs 174 workers.
-
When Codexis went public?
Codexis, Inc. is publicly traded company for more then 15 years since IPO on 22 Apr 2010.
-
What is Codexis's official website?
The official website for Codexis is codexis.com.
-
Where are Codexis's headquarters?
Codexis is headquartered at 200 Penobscot Drive, Redwood City, CA.
-
How can i contact Codexis?
Codexis's mailing address is 200 Penobscot Drive, Redwood City, CA and company can be reached via phone at +65 04218100.
Codexis company profile:
Codexis, Inc.
codexis.comExchange:
NASDAQ
Full time employees:
174
Industry:
Biotechnology
Sector:
Healthcare
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
200 Penobscot Drive
Redwood City, CA 94063
Redwood City, CA 94063
CIK: 0001200375
ISIN: US1920051067
CUSIP: 192005106
